Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release

Journal of Immunology

Volumn 192, Issue 6, 2014, Pages 2837-2845

  Samstad, Eivind O ^a   Niyonzima, Nathalie ^a   Nymo, Stig ^b,c,d   Aune, Marie H ^a   Ryan, Liv ^a   Bakke, Siril S ^a   Lappegård, Knut T ^c,d   Brekke, Ole Lars ^c,d   Lambris, John D ^e   Damås, Jan K ^a   Latz, Eicke ^a,f   Mollnes, Tom E ^a,b,c,d   Espevik, Terje ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORDLAND HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CHOLESTEROL; CHOLESTEROL CRYSTAL; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C5A; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 3; CYTOKINE; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

BLOTTING, WESTERN; CASPASE 1; CELLS, CULTURED; CHOLESTEROL; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C5; COMPLEMENT C5A; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGE-1 ANTIGEN; MICROSCOPY, CONFOCAL; MONOCYTES; PHAGOCYTOSIS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897491455     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302484     Document Type: Article

References (41)

1. Small, D. M. 1988. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 8: 103-129.
2. Abela, G. S. 2010. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J. Clin. Lipidol. 4: 156-164.
3. Stary, H. C., A. B. Chandler, R. E. Dinsmore, V. Fuster, S. Glagov, W. Insull, Jr., M. E. Rosenfeld, C. J. Schwartz, W. D. Wagner, and R. W. Wissler. 1995. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 15: 1512-1531.
4. Duewell, P., H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nuñez, M. Schnurr, et al. 2010. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357-1361.
5. Sheedy, F. J., A. Grebe, K. J. Rayner, P. Kalantari, B. Ramkhelawon, S. B. Carpenter, C. E. Becker, H. N. Ediriweera, A. E. Mullick, D. T. Golenbock, et al. 2013. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14: 812-820.
6. Stewart, C. R., L. M. Stuart, K. Wilkinson, J. M. van Gils, J. Deng, A. Halle, K. J. Rayner, L. Boyer, R. Zhong, W. A. Frazier, et al. 2010. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11: 155-161.
7. Rajamäki, K., J. Lappalainen, K. Oörni, E. Välimäki, S. Matikainen, P. T. Kovanen, and K. K. Eklund. 2010. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5: e11765.
8. Galea, J., J. Armstrong, P. Gadsdon, H. Holden, S. E. Francis, and C. M. Holt. 1996. Interleukin-1b in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16: 1000-1006.
9. Bauernfeind, F. G., G. Horvath, A. Stutz, E. S. Alnemri, K. MacDonald, D. Speert, T. Fernandes-Alnemri, J. Wu, B. G. Monks, K. A. Fitzgerald, et al. 2009. Cutting edge: NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183: 787-791.
10. Martinon, F., A. Mayor, and J. Tschopp. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27: 229-265.
11. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46: 2753-2766.
12. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
13. Qu, H., D. Ricklin, H. Bai, H. Chen, E. S. Reis, M. Maciejewski, A. Tzekou, R. A. DeAngelis, R. R. Resuello, F. Lupu, et al. 2013. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 218: 496-505.
14. Finch, A. M., A. K. Wong, N. J. Paczkowski, S. K. Wadi, D. J. Craik, D. P. Fairlie, and S. M. Taylor. 1999. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42: 1965-1974.
15. Husebye, H., M. H. Aune, J. Stenvik, E. Samstad, F. Skjeldal, O. Halaas, N. J. Nilsen, H. Stenmark, E. Latz, E. Lien, et al. 2010. The Rab11a GTPase controls Toll-like receptor 4-induced activation of interferon regulatory factor-3 on phagosomes. Immunity 33: 583-596.
16. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegård, J. Köhl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
17. Fure, H., E. W. Nielsen, C. E. Hack, and T. E. Mollnes. 1997. A neoepitopebased enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand. J. Immunol. 46: 553-557.
18. Brekke, O. L., D. Christiansen, H. Fure, M. Fung, and T. E. Mollnes. 2007. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J. Leukoc. Biol. 81: 1404-1413.
19. Grimnes, G., H. Beckman, K. T. Lappegård, T. E. Mollnes, and V. Skogen. 2011. Recurrent meningococcal sepsis in a presumptive immunocompetent host shown to be complement C5 deficient-A case report. APMIS 119: 479-484.
20. Lappegård, K. T., D. Christiansen, A. Pharo, E. B. Thorgersen, B. C. Hellerud, J. Lindstad, E. W. Nielsen, G. Bergseth, D. Fadnes, T. G. Abrahamsen, et al. 2009. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. USA 106: 15861-15866.
21. Manthey, H. D., T. M. Woodruff, S. M. Taylor, and P. N. Monk. 2009. Complement component 5a (C5a). Int. J. Biochem. Cell Biol. 41: 2114-2117.
22. Hammerschmidt, D. E., C. S. Greenberg, O. Yamada, P. R. Craddock, and H. S. Jacob. 1981. Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. J. Lab. Clin. Med. 98: 68-77.
23. Seifert, P. S., and M. D. Kazatchkine. 1987. Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol. Immunol. 24: 1303-1308.
24. Vogt, W., I. von Zabern, B. Damerau, D. Hesse, B. Lühmann, and R. Nolte. 1985. Mechanisms of complement activation by crystalline cholesterol. Mol. Immunol. 22: 101-106.
25. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway revisited. J. Cell. Mol. Med. 12: 1074-1084.
26. Harboe, M., G. Ulvund, L. Vien, M. Fung, and T. E. Mollnes. 2004. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138: 439-446.
27. Ward, P. A. 2010. The harmful role of C5a on innate immunity in sepsis. J. Innate Immun. 2: 439-445.
28. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
29. Okusawa, S., K. B. Yancey, J. W. van der Meer, S. Endres, G. Lonnemann, K. Hefter, M. M. Frank, J. F. Burke, C. A. Dinarello, and J. A. Gelfand. 1988. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1b and interleukin 1a. J. Exp. Med. 168: 443-448.
30. Schindler, R., J. A. Gelfand, and C. A. Dinarello. 1990. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood 76: 1631-1638.
31. Cole, D. S., and B. P. Morgan. 2003. Beyond lysis: how complement influences cell fate. Clin. Sci. 104: 455-466.
32. Morgan, B. P. 1989. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264: 1-14.
33. Chen, Y., C. Yang, N. Jin, Z. Xie, Y. Tang, L. Fei, Z. Jia, and Y. Wu. 2007. Terminal complement complex C5b-9-treated human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization. Eur. J. Immunol. 37: 167-176.
34. David, S., L. Biancone, C. Caserta, B. Bussolati, V. Cambi, and G. Camussi. 1997. Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol. Dial. Transplant. 12: 51-56.
35. Triantafilou, K., T. R. Hughes, M. Triantafilou, and B. P. Morgan. 2013. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J. Cell Sci. 126: 2903-2913.
36. Guarda, G., M. Zenger, A. S. Yazdi, K. Schroder, I. Ferrero, P. Menu, A. Tardivel, C. Mattmann, and J. Tschopp. 2011. Differential expression of NLRP3 among hematopoietic cells. J. Immunol. 186: 2529-2534.
37. Riedemann, N. C., R. F. Guo, V. J. Sarma, I. J. Laudes, M. Huber-Lang, R. L. Warner, E. A. Albrecht, C. L. Speyer, and P. A. Ward. 2002. Expression and function of the C5a receptor in rat alveolar epithelial cells. J. Immunol. 168: 1919-1925.
38. Dostert, C., V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677.
39. Speidl, W. S., M. Exner, J. Amighi, S. P. Kastl, G. Zorn, G. Maurer, O. Wagner, K. Huber, E. Minar, J. Wojta, and M. Schillinger. 2005. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur. Heart J. 26: 2294-2299.
40. Manthey, H. D., A. C. Thomas, I. A. Shiels, A. Zernecke, T. M. Woodruff, B. Rolfe, and S. M. Taylor. 2011. Complement C5a inhibition reduces atherosclerosis in ApoE2/2 mice. FASEB J. 25: 2447-2455.
41. Ridker, P. M., T. Thuren, A. Zalewski, and P. Libby. 2011. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162: 597-605.